Article Text

Download PDFPDF
Randomised controlled trial
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests AJS worked as a clinical investigator enrolling four participants in this double-blind placebo-controlled EMPA-REG OUTCOME trial.

  • Provenance and peer review Commissioned; internally peer reviewed.